Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$28.30 +1.0%	$29.00	$0.93 ▼ $79.02	$199.84M	-6.01	825,786 shs	18,963 shs
MGX Metagenomi	$1.65 +2.7%	$1.59	$1.23 ▼ $5.50	$62.43M	-0.38	840,010 shs	262,662 shs
PVLA Palvella Therapeutics	$24.12 +1.2%	$23.29	$6.20 ▼ $29.27	$266.66M	-0.11	132,679 shs	40,233 shs
RZLT Rezolute	$4.78 -1.7%	$4.09	$2.22 ▼ $6.19	$412.20M	1.03	645,529 shs	613,041 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	0.00%	+21.62%	+2.72%	-11.67%	+2,544.86%
MGX Metagenomi	0.00%	+13.29%	-2.71%	+17.30%	-57.70%
PVLA Palvella Therapeutics	0.00%	+9.24%	+1.30%	+0.58%	+2,411,999,900.00%
RZLT Rezolute	0.00%	+9.77%	+12.35%	+88.74%	+14.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRUG Bright Minds Biosciences	2.9231 of 5 stars	3.6	3.0	3.0	2.5	0.0
MGX Metagenomi	1.7961 of 5 stars	3.5	2.0	0.0	1.7	0.6
PVLA Palvella Therapeutics	3.4162 of 5 stars	3.6	0.0	2.8	4.2	0.6
RZLT Rezolute	3.085 of 5 stars	3.6	1.0	3.8	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	194.17% Upside
MGX Metagenomi	3.00	Buy	$13.00	685.97% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	91.90% Upside
RZLT Rezolute	3.14	Buy	$11.83	147.82% Upside

Current Analyst Ratings Breakdown

Latest MGX, DRUG, PVLA, and RZLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
MGX Metagenomi	$52.29M	1.18	N/A	N/A	$6.28 per share	0.26
PVLA Palvella Therapeutics	$42.81M	6.23	N/A	N/A	$5.58 per share	4.32
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)

Latest MGX, DRUG, PVLA, and RZLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	126.01	126.01
MGX Metagenomi	N/A	5.85	5.85
PVLA Palvella Therapeutics	N/A	8.84	8.84
RZLT Rezolute	N/A	8.43	8.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
MGX Metagenomi	N/A
PVLA Palvella Therapeutics	40.11%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
MGX Metagenomi	17.80%
PVLA Palvella Therapeutics	20.50%
RZLT Rezolute	18.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
RZLT Rezolute	40	85.52 million	69.79 million	Optionable

MGX, DRUG, PVLA, and RZLT Headlines

Recent News About These Companies

Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 27, 2025 | insidertrades.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Insider Buys 2,500 Shares of Stock

June 26, 2025 | marketbeat.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Acquires 1,230,769 Shares of Stock

June 26, 2025 | americanbankingnews.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

June 25, 2025 | insidertrades.com

Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $20,250.00 in Stock

June 24, 2025 | marketbeat.com

Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 24, 2025 | insidertrades.com

Young-Jin Kim Acquires 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 23, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Buy" from Analysts

June 14, 2025 | marketbeat.com

Bank of America Corp DE Has $443,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT)

June 12, 2025 | marketbeat.com

69,724 Shares in Rezolute, Inc. (NASDAQ:RZLT) Bought by Ameriprise Financial Inc.

June 6, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%

June 3, 2025 | finance.yahoo.com

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025 | globenewswire.com

Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 21, 2025 | finanznachrichten.de

Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential

May 20, 2025 | finance.yahoo.com

Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment

May 15, 2025 | nasdaq.com

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

FDA grants breakthrough status to Rezolute’s hypoglycemia therapy

May 6, 2025 | investing.com

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025 | globenewswire.com

Rezolute to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025 | seekingalpha.com

Rezolute Closes $96.9 Million Underwritten Offering

April 28, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
By Gabriel Osorio-Mazilli | July 3, 2025
View Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
By Leo Miller | June 12, 2025
View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

MGX, DRUG, PVLA, and RZLT Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$28.30 +0.29 (+1.04%)

Closing price 07/3/2025 03:27 PM Eastern

Extended Trading

$27.00 -1.30 (-4.59%)

As of 07/3/2025 04:11 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Metagenomi NASDAQ:MGX

$1.65 +0.04 (+2.73%)

Closing price 07/3/2025 03:43 PM Eastern

Extended Trading

$1.66 +0.00 (+0.06%)

As of 07/3/2025 04:36 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Palvella Therapeutics NASDAQ:PVLA

$24.12 +0.29 (+1.22%)

As of 07/3/2025 01:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Rezolute NASDAQ:RZLT

$4.78 -0.09 (-1.75%)

Closing price 07/3/2025 03:04 PM Eastern

Extended Trading

$4.78 0.00 (0.00%)

As of 07/3/2025 04:01 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time